| Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. | |
| | |
MedLine Citation:
|
PMID: 22250059 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Diabetes is a leading cause of death and disability, and its prevalence is increasing. When diet fails, patients with type 2 diabetes mellitus (T2DM) are prescribed oral hypoglycemics for glycemic control. Few studies have explored initial use or change from initial oral hypoglycemic therapy in the primary care setting. We aimed to describe the utilization of initial oral hypoglycemics among newly diagnosed patients with diabetes from 1998-2009 and changes from initial to subsequent therapy among patients prescribed older oral hypoglycemic agents using electronic health records. METHODS: This observational cohort study used electronic health records from newly diagnosed patients with T2DM between 1 January 1998 and 31 March 2009 at two large health systems in the USA. Oral hypoglycemics included older (biguanide, sulfonylurea, and thiazolidinedione) and newer agents (incretin mimetic agents, alpha-glucosidase inhibitors, and D-phenylalanine derivatives). Multinomial regression models were fit to evaluate initial older oral hypoglycemic medication. We used incidence density sampling and conditional logistic regression models to evaluate predictors of regimen change. RESULTS: Most patients were treated from the biguanide class of oral hypoglycemics (67%), but there were differences in initial prescribing by age and race. HbA1c (Odds Ratio for HbA1c 7.0-8.9 vs < 7.0, 5.87 [95% Confidence Interval: 3.62-9.52]; Odds Ratio for HbA1c ≥ 9 vs < 7.0, 20.25 [95% Confidence Interval: 8.32-49.29] and Black people (Odds Ratio, 0.29 [95% Confidence Interval: 0.14, 0.60]) versus White people were associated with regimen change in the adjusted analysis. CONCLUSIONS: Clinical and demographic characteristics influence choice and duration of initial oral hypoglycemic treatment as well as regimen changes. Copyright © 2012 John Wiley & Sons, Ltd. |
| | |
Authors:
|
Emily S Brouwer; Suzanne L West; Marianne Kluckman; Dennis Wallace; Andrew L Masica; Edward Ewen; Rustam Kudyakov; Dunlei Cheng; James Bowen; Neil S Fleming |
Related Documents
:
|
9237779 - Gestational diabetes mellitus and gene mutations which affect insulin secretion. 20577119 - Pharmacogenetic association of hypertension candidate genes with fasting glucose in the... 10803679 - Nat2 polymorphism associated with plasma glucose concentration in canadian oji-cree. 10753039 - The tumour necrosis factor alpha -238 g --> a and -308 g --> a promoter polymorphisms a... 20107109 - The t-allele of tcf7l2 rs7903146 associates with a reduced compensation of insulin secr... 12829659 - Promoter polymorphisms of the tnf-alpha (g-308a) and il-6 (c-174g) genes predict the co... 19684369 - The insulin immunoassay after 50 years: a reassessment. 21840149 - The influence of diabetes psychosocial attributes and self-management practices on chan... 18370749 - Glycemic control in the metabolic syndrome and implications in preventing cardiovascula... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-16 |
Journal Detail:
|
Title: Pharmacoepidemiology and drug safety Volume: - ISSN: 1099-1557 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9208369 Medline TA: Pharmacoepidemiol Drug Saf Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 John Wiley & Sons, Ltd. |
Affiliation:
|
RTI International, Research Triangle Park, NC, USA; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An O-Centered Structure of the Trinuclear Copper Center in the Cys500Ser/Glu506Gln Mutant of CueO an...
Next Document: From Monolayer to Multilayer N-Channel Polymeric Field-Effect Transistors with Precise Conformationa...